On our Singapore Home Brew segment on the Saturday Mornings Show hosted by Glenn van Zutphen: In this episode, we delve into Singapore’s pivotal role in the global fight against Alzheimer’s disease, spotlighting the recent approval of LEQEMBI® by the Singapore Health Sciences Authority. Clinically proven to slow disease progression in early-stage patients, LEQEMBI® is a huge leap forward for treating symptoms and modifying the course of the disease in some patients. This milestone comes as more than 92,000 people in Singapore currently live with dementia, a number expected to rise sharply in the coming years. As the only Southeast Asian site in the international clinical trial, National University Hospital of Singapore played a key part in this breakthrough, with promising results confirmed in the Asian sub-analysis. Joining us to unpack this development are two leading voices in neurology and aging: Professor Christopher Chen, Visiting Consultant at National University Hospital and Director of the Memory, Ageing and Cognition Centre, and Associate Professor Adeline Ng, Senior Consultant in Neurology at the National Neuroscience Institute. They offer insights not just from a medical perspective, but also from the institutional frontlines where science meets healthcare policy and patient care. We explore how this treatment could transform the future for patients and caregivers in Singapore—offering more time, more clarity, and renewed hope.

See omnystudio.com/listener for privacy information.